Short Communication

Generation of transgenic corn-derived *Actinobacillus pleuropneumoniae* ApxIIA fused with the cholera toxin B subunit as a vaccine candidate

Min-Kyoung Shin¹, Myung Hwan Jung¹, Won-Jung Lee¹, Pil Son Choi², Yong-Suk Jang³, Han Sang Yoo¹,*

¹ Department of Infectious Disease, College of Veterinary Medicine and Brain Korea 21 Program for Veterinary Science, Seoul National University, Seoul 151-742, Korea
² Department of Medicinal Plant Resources, Nambu University, Gwangju 506-824, Korea
³ Division of Biological Sciences and the Institute for Molecular Biology and Genetics, Chonbuk National University, Jeonju 561-756, Korea

Corn, one of the most important forage crops worldwide, has proven to be a useful expression vehicle due to the availability of established transformation procedures for this well-studied plant. The exotoxin Apx, a major virulence factor, is recognized as a common antigen of *Actinobacillus* (*A.*.) *pleuropneumoniae*, the causative agent of porcine pleuropneumonia. In this study, a cholera toxin B (CTB)-ApxIIA#5 fusion protein and full-size ApxIIA expressed in corn seed, as a subunit vaccine candidate, were observed to induce Apx-specific immune responses in mice. These results suggest that transgenic corn-derived ApxIIA and CTB-ApxIIA#5 proteins are potential vaccine candidates against *A. pleuropneumoniae* infection.

Keywords: *Actinobacillus pleuropneumoniae*, ApxIIA, cholera toxin B subunit protein, transgenic plant

Transgenic plants have been used for the production and delivery of edible oral subunit vaccines [3,10]. Plant-based vaccines possess some advantages over other types of vaccine biotechnology such as increased safety, anticipated low cost of mass vaccination programs, and wider use of vaccines for veterinary medicine [9,10]. Several plant-derived vaccine candidates have been developed, and their immunogenicity and ability to protect against microbial infection were evaluated [3]. Corn, a major forage crop, is a particularly attractive expression vehicle due to its extensively studied genetics and amenability to established transformation procedures [7]. In addition, grain seeds provide excellent systems for oral delivery of subunit vaccines because of their low water content and long shelf-life [7].

*Actinobacillus* (*A.*) *pleuropneumoniae* is the etiological agent of severe hemorrhagic, necrotizing pneumonia often associated with fibrinous pleuritis in pigs, and is responsible for significant economic losses worldwide [2]. Among several virulence factors such as exotoxins, lipopolysaccharides, capsular polysaccharide, membrane proteins, and adhesion factors, the Apx exotoxin is believed to be correlated with *A. pleuropneumoniae* virulence [2]. Apx toxins are highly immunogenic and induce a substantial production of antibodies during *A. pleuropneumoniae* infection [4]. ApxII is expressed by all but serotype 10, while ApxI and ApxIII are expressed by different serotypes in various combinations [2]. In addition, serovars producing ApxI and ApxII are the most virulent. Therefore, ApxII could effectively serve as an antigen for vaccines against *A. pleuropneumoniae*. ApxIIA, which is expressed in *Saccharomyces cerevisiae* and transgenic tobacco, has previously been reported to be capable of inducing protective immune responses against *A. pleuropneumoniae* in mice [6,8,12]. The neutralizing epitope of ApxIIA (ApxIIA#5) from *A. pleuropneumoniae* serotype 2 was isolated in Korea and found to induce a protective immune response against *A. pleuropneumoniae*. Smaller fragments of this epitope are easily expressed in large quantities using a heterologous expression system [11].

Cholera toxin B (CTB) binds to GM1-ganglioside at the surface of mammalian intestinal epithelial cells, including the M cells of gut-associated lymphoid tissue [1]. The CTB subunit protein has also been found to induce mucosal immunity as an effective carrier molecule [1]. Therefore, it was chosen as a fusion protein for the present study.

The generation of transgenic corn expressing CTB-ApxIIA#5 fusion protein (0.93 kb) and full-size (2.8 kb) ApxIIA has been previously described [5]. One gram of the corns expressing the CTB-ApxIIA#5 fusion protein or full-size ApxIIA was ground in liquid nitrogen using a
mortar and pestle. Soluble proteins were extracted at a solid-to-liquid ratio of 1:10 with phosphate buffered saline (PBS). The extracted protein was subcutaneously injected into the mice to evaluate the immunogenicity of the transgenic corn-derived ApxIIA and CTB-ApxIIA#5 fusion proteins. Four-week-old ICR female mice ( Orient Bio, Korea) were used through this study following policy and regulation for the care and use of laboratory animal (Laboratory Animal Center, Seoul National University, Korea). The mice were divided into three groups: a non-vaccinated control group and groups that received injections of the CTB-ApxIIA#5 fusion protein or full-size ApxIIA. Four mice in each group were boosted subcutaneously with 200 μL of soluble antigen extracts mixed with complete Freund’s adjuvant (Sigma, USA), and were injected twice with the same antigen mixed with incomplete Freund’s adjuvant (Sigma, USA).

Blood samples and spleens were collected 2 weeks after the final immunization. A spleen cell suspension was prepared by gently pressing and straining the spleen tissue through a 100-μm pore nylon cell strainer (100 μm; BD Falcon, USA) with a plunger. A 5 × 10^6 cells/mL suspension was cultured for 5 days in RPMI-1640 medium (Gibco-BRL, USA) supplemented with 10% fetal bovine serum (Gibco-BRL, USA) at 37°C in 5% CO2. Spleen cells of each group were stimulated with the recombinant ApxIIA (2 μg/mL), and Concanavalin A (ConA, 2 μg/mL) to evaluate production of interferon (IFN)-γ, interleukin (IL)-4, and nitric oxide (NO).

After stimulation, the secreted concentration of IFN-γ and IL-4 was measured using the enzyme-linked immunosorbent assay (ELISA) kit (eBioscience, USA) according to the manufacturer’s instructions. The levels of NO derived from the culture supernatant were determined by the Griess method [13]. ApxIIA-specific IgG and IgA-memory B cell enzyme-linked immunospot (ELISPOT) assays were performed using mouse Ig G and IgA ELISPOT kits (Mabtech, USA) according to the manufacture’s instruction.

The level of antigen-specific antibody in serum was determined with an ELISA. For this, 96-well microplates were coated with 1 μg/mL of the recombinant ApxIIA antigen and incubated overnight at 4°C. The plates were then blocked with 1% bovine serum albumin (Sigma, USA) in a solution of PBS containing 0.1% Triton X-100 (PBST) for 2 h at 37°C. After washing with PBST, 1:20 diluted mice sera were added to each well and incubated for 1 h at 37°C. Goat anti-mouse IgG (H + L)-HRP conjugate (Bio-Rad, USA) or anti-mouse IgA (α-chain specific)-HRP conjugate (Bethyl, USA) was used at 1:2,000 as a secondary antibody, and 2,2’-azin-bis (3-ethylbenzthiazoline-6-sulfonic acid) substrate (Bio-Rad, USA) was added to develop the color. Optical density was measured at 405 nm using an Emax Precision microplate reader ( Molecular Devices, USA). Statistical significance was analyzed with Student’s t-test using SPSS (ver 17.0; SPSS, USA). Differences were considered significant if a p-value < 0.05 was obtained.

The level of ApxIIA-specific IgG antibodies significantly increased in serum from the mice boosted with the CTB-ApxIIA#5 fusion protein and full-size ApxIIA from the transgenic corn compared to the control mice at the time of the final booster shots (p < 0.01). However, there were no significant differences in the anti-ApxIIA IgA antibody responses between the injected groups and the control group (Fig. 1). The production of ApxIIA-specific IgG memory B cells was observed in spleens from the mice boosted with the CTB-ApxIIA#5 fusion protein and full-size-ApxIIA by ELISPOT (p < 0.01) from the transgenic corn (Fig. 2). In addition, ApxIIA-specific IgA memory B cells were produced in the mice injected with the CTB-ApxIIA#5 fusion protein (p < 0.05; Fig. 2). The secretion of IFN-γ, IL-4, and NO from spleen cells was measured as an indicator of immune response induction. After in vitro stimulation, spleen cells from the group injected with full-size ApxIIA produced high levels of IFN-γ, a T helper type 1 cytokine (p < 0.05; Fig. 3), while the production of IL-4, a T helper type 2 (Th2) cytokine, was not detected in any group (data not shown). The transgenic corn-derived ApxIIA, particularly the CTB-
ApixA#5 fusion protein, was found to induce the production of antigen-specific antibodies (Figs. 1 and 2), although IL-4 related to a Th2 immune response was not detected. In addition, high NO production was detected in the mice treated with the CTB-ApixA#5 fusion protein and full-size ApxIIA after in vitro stimulation (p < 0.01; Fig. 3).

Based on the induced antigen-specific immune responses, we concluded that the transgenic corn-derived CTB-ApixA#5 fusion protein and full-size ApxIIA are capable of effectivly inducing Apx-specific immune responses in mice. In particular, the group injected with the CTB-ApixA#5 fusion protein showed higher ApxIIA-specific antibody titer than the group injected with the full-size ApxIIA. Fusing the ApixA#5 antigenic fragment with the CTB protein could be thought to improve the efficiency of antigen delivery to the host immune system based on these results. Moreover, the small size of the ApxIIA epitope contributes to increased expression levels in a heterologous expression system [11]. Consequently, the transgenic corn expressing the CTB-ApixA#5 fusion protein and full-size ApxIIA is a promising candidate for an effective vaccine against A. pleuropneumoniae. We are currently preparing for further experiments to develop a transgenic corn-derived oral vaccine against A. pleuropneumoniae based on the results of the present study.

Acknowledgments

This work was supported by a grant (PJ007044) from the BioGreen 21 Program, the Rural Development Administration (RDA), and Research Institute of Veterinary Science, BK 21 for Veterinary Science, Seoul National University, Korea.

References

1. Arakawa T, Chong DKX, Merritt JL, Langridge WHR.
2. Bossé JT, Janson H, Sheehan BJ, Beddek AJ, Rycroft AN, Kroll JS, Langford PR. Actinobacillus pleuropneumoniae: pathobiology and pathogenesis of infection. Microbes Infect 2002, 4, 225-235.
3. Floss DM, Falkenburg D, Conrad U. Production of vaccines and therapeutic antibodies for veterinary applications in transgenic plants: an overview. Transgenic Res 2007, 16, 315-332.
4. Frey J, Nicolet J. Immunological properties of Actinobacillus pleuropneumoniae hemolysin I. Vet Microbiol 1991, 28, 61-73.
5. Kim HA, Yoo HS, Yang MS, Kwon SY, Kim JS, Choi PS. The development of transgenic maize expressing Actinobacillus pleuropneumoniae ApxIIA gene using Agrobacterium. J Plant Biotechnol 2010, 37, 313-318.
6. Kim JM, Jung DI, Eom YJ, Park SM, Yoo HS, Jang YS, Yang MS, Kim DH. Surface-displayed expression of a neutralizing epitope of ApxIIA exotoxin in Saccharomyces cerevisiae and oral administration of it for protective immune responses against challenge by Actinobacillus pleuropneumoniae. Biosci Biotechnol Biochem 2010, 74, 1362-1367.
7. Lamphear BJ, Jilka JM, Kesl L, Welter M, Howard JA, Streathfield SJ. A corn-based delivery system for animal vaccines: an oral transmissible gastroenteritis virus vaccine boosts lactogenic immunity in swine. Vaccine 2004, 22, 2420-2424.
8. Lee KY, Kim DH, Kang TJ, Kim J, Chung GH, Yoo HS, Arntzen CJ, Yang MS, Jang YS. Induction of protective immune responses against the challenge of Actinobacillus pleuropneumoniae by the oral administration of transgenic tobacco plant expressing ApxIIA toxin from the bacteria. FEMS Immunol Med Microbiol 2006, 48, 381-389.
9. Mason HS, Warzecha H, Mor T, Arntzen CJ. Edible plant vaccines: applications for prophylactic and therapeutic molecular medicine. Trends Mol Med 2002, 8, 324-329.
10. Sala F, Manuela Rigano M, Barbante A, Basso B, Walmsley AM, Castiglia S. Vaccine antigen production in transgenic plants: strategies, gene constructs and perspectives. Vaccine 2003, 21, 803-808.
11. Seo KW, Kim DH, Kim AH, Yoo HS, Lee KY, Jang YS. Characterization of antigenic determinants in ApxIIA exotoxin capable of inducing protective immunity to Actinobacillus pleuropneumoniae challenge. Immunol Invest 2011, 40, 465-480.
12. Shin SJ, Bae JL, Cho YW, Lee DY, Kim DH, Yang MS, Jang YS, Yoo HS. Induction of antigen-specific immune responses by oral vaccination with Saccharomyces cerevisiae expressing Actinobacillus pleuropneumoniae ApxIIA. FEMS Immunol Med Microbiol 2005, 43, 155-164.
13. Sosroseno W, Barid I, Herminajeng E, Susilowati H. Nitric oxide production by a murine macrophage cell line (RAW264.7) stimulated with lipopolysaccharide from Actinobacillus actinomycetemcomitans. Oral Microbiol Immunol 2002, 17, 72-78.